Evgen Pharma plc
("Evgen", the "Company" or the "Group")
Director / PDMR Shareholding
5 April 2024 - Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces that certain Directors and Persons Discharging Managerial Responsibility ("PDMRs") have subscribed for new Ordinary Shares amounting to an aggregate subscription for 8,600,000 new Ordinary Shares through the Placing or the Subscription or pursuant to the terms of the Acquisition announced on 19 March 2024, as follows:
| Director | Number of Existing Ordinary Shares held | Number of New Ordinary Shares being subscribed | Number of Initial Consideration Shares being allotted pursuant to the Acquisition | Total number of Ordinary Shares immediately following Admission | Percentage of Issued Share Capital following Admission |
| Dr Huw Jones (CEO) | 62,500 | 3,000,000 | 122,293** | 3,184,793 | 0.75% |
| Toni Hänninen (CFO)* | 0 | 1,000,000 | 0 | 1,000,000 | 0.23% |
| Dr Susan Foden (Chair) | 125,000 | 600,000 | 0 | 725,000 | 0.17% |
| Dr Helen Kuhlman (PDMR) | 55,744 | 1,000,000 | 0 | 1,055,744 | 0.25% |
| Dr Glen Clack (PDMR)*** | 0 | 1,000,000 | 0 | 1,000,000 | 0.23% |
| Dr Nicholas Mallard (PDMR) | 20,771 | 2,000,000 | 0 | 2,020,771 | 0.47% |
\* Toni Hänninen participated via Borealito GmbH (a company wholly owned by him).
** Dr Huw Jones has a shareholding of 96,350 shares in Chronos Therapeutics and will as result be receiving 122,293 Initial Consideration Shares in Evgen on completion of the Acquisition.
***Dr Glen Clack participated via Ailse Oncology Ltd (a company wholly owned by him).
Unless otherwise defined herein, terms used in this announcement have the meaning given to them in the Acquisition, Fundraising and Change of Name announcement dated 19 March 2024.
Enquiries
| Evgen Pharma plc Dr Helen Kuhlman, CBO | +44 207 457 2020 |
| Cavendish Capital Markets (NOMAD and Broker) | +44 20 7220 0500 |
| Instinctif Partners Melanie Toyne-Sewell / Jack Kincade | +44 207 457 2020 |
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the highly biologically active compound sulforaphane and novel proprietary analogues based on sulforaphane.
The Company's lead asset, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin and has undergone clinical trials for oestrogen-positive (ER+) metastatic breast cancer and recently a Phase 1b study of the Company's new enteric coated tablet formulation. The FDA has granted Orphan Drug status to SFX-01 in malignant glioma. SFX-01 will be investigated initially in this indication as an investigator sponsored study in the Netherlands.
The Company also has a wide number of collaborations with leading academic centres in the UK, Europe and the US as part of the continuing strategy to build the scientific data for the compound. Recently, Evgen completed an out-licensing transaction with Stalicla SA, a Swiss specialist company in neurodevelopmental disorders, commencing with autism spectrum disorder. The deal, if successful, will generate milestone payments of $160.5m and a double-digit royalty on sales.
The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com.
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
| 1. | Details of the person discharging managerial responsibilities / person closely associated | ||||||||||
| a) | Name | Dr Huw Jones | |||||||||
| 2. | Reason for the Notification | ||||||||||
| a) | Position/status | Chief Executive Officer | |||||||||
| b) | Initial notification/Amendment | Initial Notification | |||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
| a) | Name | Evgen Pharma plc | |||||||||
| b) | LEI | 213800NO3E6TSTQO8K20 | |||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each | |||||||||
| Identification code | GB00BSVYN304 | ||||||||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares and receipt of Consideration Shares | |||||||||
| c) | Price(s) and volume(s) |
| |||||||||
| d) | Aggregated information: · Aggregated volume · Price | As above | |||||||||
| e) | Date of the transaction | 5 April 2024 | |||||||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | |||||||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Toni Hänninen | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Financial Officer | ||||
| b) | Initial notification/Amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Evgen Pharma plc | ||||
| b) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each | ||||
| Identification code | GB00BSVYN304 | |||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | As above | ||||
| e) | Date of the transaction | 5 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Susan Foden | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Non-Executive Chair | ||||
| b) | Initial notification/Amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Evgen Pharma plc | ||||
| b) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each
| ||||
| Identification code | GB00BSVYN304 | |||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | As above | ||||
| e) | Date of the transaction | 5 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Helen Kuhlman | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Business Office / PDMR | ||||
| b) | Initial notification/Amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Evgen Pharma plc | ||||
| b) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each
| ||||
| Identification code | GB00BSVYN304 | |||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | As above | ||||
| e) | Date of the transaction | 5 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Glen Clack | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Medical Officer / PDMR | ||||
| b) | Initial notification/Amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Evgen Pharma plc | ||||
| b) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each
| ||||
| Identification code | GB00BSVYN304 | |||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | As above | ||||
| e) | Date of the transaction | 5 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Dr Nicholas Mallard | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | PDMR | ||||
| b) | Initial notification/Amendment | Initial Notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Evgen Pharma plc | ||||
| b) | LEI | 213800NO3E6TSTQO8K20 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument |
Ordinary Shares of 0.25p each
| ||||
| Identification code | GB00BSVYN304 | |||||
| b) | Nature of the transaction | Purchase of new Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price | As above | ||||
| e) | Date of the transaction | 5 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM Market | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.